Basic fibroblast growth factor (bFGF) is a polypeptide that supports the survival of brain cells (in cluding neurons, glia, and endothelia) and protects neu rons against a number qf toxins and insults in vitro. This factor is also a potent dilator of cerebral pial arterioles in vivo. In previous studies, we found that intraventricularly administered bFGF reduced infarct volume in a model of focal cerebral ischemia in rats. In the current study, bFGF (45 I-lg/kg/h) in vehicle, or vehicle alone, was in fused intravenously for 3 h, beginning at }O min after permanent middle cerebral artery occlusion by intralumi nal suture in mature Sprague-Dawley rats. After 24 h, neurological deficit (as assessed by a 0-to 5-point scale, with 5 = most severe) was 2.6 ± 1.0 in vehicle-treated "Neurotrophic" growth factors are polypeptides that, acting through specific receptors, initiate cas cades of signal transduction resulting in increased neuronal survival. Recently, it has been appreciated that these factors also protect neurons against var ious insults and toxins. In particular, basic fibro blast growth factor (bFGF) is a 154-amino acid, 18-kD polypeptide that supports the survival of a wide Abbreviations used: bFGF, basic fibroblast growth factor; BSA, bovine serum albumin; EAA, excitatory amino acid; MCA, middle cerebral artery; NO, nitric oxide; TTC, 2,3,5-tri phenyltetrazolium hydrochloride.
and 1.5 ± 1.3 in bFGF-treated rats (mean ± SD; N = 12 vs. 11; p = 0.009). Infarct volume was 297 ± 65 mm3 in vehicle-and 143 ± 135 mm3 in bFGF -treated animals (p = 0.002). During infusion, there was a modest decrease in mean arterial blood pressure but no changes in arterial blood gases or core or brain temperature in bFGF-treated rats. Autoradiography following intravenous administra tion of III In-labeled bFGF showed that labeled bFGF crossed the damaged blood-brain barrier to enter the ischemic (but not the nonischemic) hemisphere. Whether the infarct-reducing effects of bFGF depend on intra parenchymal or intravascular mechanisms requires fur ther study. Key Words: Basic fibroblast growth factor Cerebral infarction-Focal cerebral ischemia. variety of neurons from the embryonic rat brain in vitro and protects cultured neurons against excit atory amino acid (EAA) toxicity, anoxia, hypogly cemia, free radicals, and nitric oxide (Walicke, 1988; Mattson et aI., 1989; Freese et aI., 1992; Fin klestein et aI., 1993; Maiese et aI., 1993; Mattson and Scheff, 1994) . In vivo bFGF protects brain neu rons against mechanical and excitotoxic injury (Anderson et aI., 1988; N ozaki et aI., 1993) . More over, this multi potential factor has trophic effects on brain glial and endothelial cells and is a potent systemic and cerebral vasodilator (Pettman et aI., 1985; Gospodarowicz et aI., 1986; Cuevas et aI., 1991; Rosenblatt et aI., 1994) .
In previous studies (Koketsu et aI., 1994) , we found that intraventricular administration of bFGF, starting at 3 days before ischemia, reduced infarct volume in a model of focal cerebral ischemia in ma ture rats. In the current study, we extended these findings to show that the intravenous administration of bFGF, beginning after ischemia, also reduced infarct volume and improved behavioral outcome in a model of permanent middle cerebral artery (MeA) occlusion.
METHODS
Male Sprague-Dawley rats (300--360 g) were allowed food and water ad libitum. Rats were then weighed and anesthetized with chloral hydrate (400 mg/kg, i.p.), and polyethylene catheters were inserted into the tail artery to monitor blood pressure and blood gases and into the in ferior vena cava through the left femoral vein for intra venous infusions. Core temperature was maintained be tween 36.8 and 37.8°C during surgery and infusions by a heating lamp connected to a rectal temperature probe (Model 73A; Yellow Springs Instruments).
Permanent occlusion of the MCA was produced by in traarterial suture, as described previously (Minematsu et aI., 1992 (Minematsu et aI., , 1993 Meadows et aI., 1994) . Briefly, a 4-0 monofilament nylon suture with a rounded tip was in serted into the right common carotid artery and then ad vanced through the internal carotid artery into the MCA for a distance of approximately 17 mm, until mild resis tance was felt. Using this technique, the tip of the suture is advanced into the origin of the anterior cerebral artery, occluding the MCA. A large infarct in the territory of the MCA is typically produced (Minematsu et aI., 1992 (Minematsu et aI., , 1993 Meadows et aI., 1994) .
Recombinant human bFGF was obtained as concen trated stock (1.15 mg/ml in 20 mM sodium citrate, 0.6 M NaCI, pH 5.0) as a generous gift from Creative Biomole cules (Hopkinton, MA, U.S.A.) and stored at -80°C be fore use. Stock solution was then diluted into vehicle con taining 0.9% NaCI and 100 fLg/ml bovine serum albumin (BSA, Boeringer-Mannheim, Mannheim, Germany), pH 7.4 -1:38 dilution), to give a final bFGF concentration of 30 fLg/ml. Animals were infused intravenously with this solution at a rate of 0.5 ml/h for 3 h, beginning at 30 min after MCA occlusion, to deliver a bFGF dose of 45 fLg/ kg/h, or 135 fLg/kg for the entire infusion period. Control animals received intravenous infusions of 0.9% saline (N = 8) or 0.9% saline with 100 fLg/ml BSA (N = 4). We found no differences in infarct volume or physiological parameters among these control animals, so the data were pooled in the analysis. In addition, in other control ex periments, we found that the "extra" trace amounts of sodium citrate (0.5 13 mM) and NaCI (16 mM) present in bFGF solutions (due to dilution of the stock solution) had no effect on infarct size or physiological parameters.
Anesthesia was maintained during infusions with sup plemental doses of chloral hydrate (100 mg/kg, i.p.). Mean arterial blood pressure (MABP) and arterial blood gases were recorded just before, 30 min after, and 3 h after MCA occlusion (the last two time points were just after and 2.5 h after the initiation of bFGF infusions). After infusions, catheters were removed, and animals were allowed to awaken from anesthesia, returned to home cages, and allowed food and water ad libitum. In traarterial sutures were left in place until sacrifice.
At 24 h after ischemia, animals were assessed by be havioral rating scale (0 = no deficit to 5 = dead), as described previously (ZeaLonga et aI., 1989) . Animals Vol. 15, No.6, 1995 were then reanesthetized with chloral hydrate and decap itated. Brains were removed and the appropriate location of the intraarterial suture was confirmed. Brains were then sectioned into 2-mm coronal slices, which were incubated in 2% 2,3,5-triphenyltetrazolium hydrochlo ride (TTC) for 30 min, and fixed in 10% buffered forma lin. This procedure stains viable tissue red; infarcted tis sue remains unstained (Koketsu et a!., 1994) . After 48 h, sections were photographed (Zeiss microscope, 0.8x magnification), and infarct size in each of five slices was determined using a computer-interfaced digitizer (Signa Scan V 3.10; Jandel Scientific, Costa Madera, CA, U.S.A.; and Numonics 2200, Numonics, Montgomer yville, PA, U.S.A.; slices 1-5-bregma coordinates +2.4, +0.4, -1.6, -3.6, and -5.4, respectively). In farct area was determined separately for cortex and cau doputamen for slices I, 2, and 3. Infarct areas on each slice were summed and multiplied by slice thickness to give infarct volumes. All infusions, behavioral ratings, and infarct analysis were done in a randomized, blinded manner.
To examine the possible effects of bFGF on brain tem perature, a separate group of intact animals (N = 3) re ceived an intravenous infusion of bFGF (45 fLg/kg/h) starting at 30 min after induction of chloral hydrate anes thesia and lasting for 3 h. Body temperature was con trolled as above, and temperature of the lateral cerebral cortex, measured by a temperature probe (Omega Group, Stamford, CT, U.S.A.) 'inserted through a small burr hole, was recorded before and at half-hour intervals dur ing bFGF infusion.
All data are expressed as mean ± SD. Continuous data were analyzed by analysis of variance or unpaired two tailed t tests with Bonferroni correction for multiple com parisons. Noncontinuous behavioral data were analyzed by Mann-Whitney U test.
To determine whether intravenously administered bFGF might cross the damaged blood-brain barrier to enter ischemic brain tissue, an additional three animals received radiolabeled bFGF and the distribution of radio activity in the brain was determined by autoradiography. To label bFGF, the protein was dissolved in 0.2 M sodium bicarbonate buffer, pH 8.1. and modified with diethylen etetraminepentaacetic acid anhydride (anhydride:bFGF, 200: 1 molar ratio; Sigma). The reaction was allowed to proceed for 20 min, and the solution was dialyzed over night. "'InCI, (DuPont) in 0.1 M sodium citrate buffer, pH 5.3, was then added for 1 h, and nonbound !l'In was removed by gel chromatography using a Sephadex G-100 column. The specific activity of labeled protein was 50 fLCi/fLg· Three hours after MCA occlusion, rats received an in travenous infusion of II 'In-labeled bFGF (20 fLg) lasting 30 min. (This time period coincides with the last 30 min of 3-h infusions given to treated animals; see above.) Four hours later, animals were anesthetized with sodium pen tobarbital (100 mg/kg i.p.) and perfusion-fixed with 0.9% saline, followed by 2% paraformaldehyde, 0.01 M so dium-m-periodate, and 0.075 M L-Iysine monohydrochlo ride, in 0.1 M sodium phosphate buffer, pH 7.4. Brains were removed and the total radioactivity determined by gamma counter. Brains were then postfixed for 20 h and cut on a vibratome (150-fLm sections), Sections were then mounted on polylysine-coated slides, allowed to dry, de hydrated in alcohol, and put on film (j3-Hypermax, Am ersham) for 7 days at -80°C. Autoradiograms were then developed with Kodak D-19 developer and nonhardening fixer.
To determine that the label found in brain remained associated with bFGF, one additional animal received ischemia surgery and intravenous IIIIn-bFGF as above, and bFGF in brain homogenate was immunoprecipitated with specific anti-bFGF serum. Tissue was homogenized (1:4, wt/vol) in 2 M NaCl, 0.1 M Tris-HCl, pH 7.56 with aproteinin, pepstatin A, leupeptin, and trypsin inhibitor (all at 2.5 j.1g/ml). The homogenate was then centrifuged, passed through a low-protein-binding filter, and concen trated by centrifugal ultrafiltration. Concentrated ho mogenate was then incubated with an excess of rabbit polyc1onal antiserum to bFGF (R16; kindly obtained from Dr. Joachim Sasse, Tampa, FL, U.S.A.), and the anti gen-antibody complex was precipitated using an immo bilized protein G kit according to the protocol of the man ufacturer (Pierce). Radioactivity in the precipitate was determined by 'Y counter. In preliminary studies, we de termined that at least 50% of authentic IIIIn-bFGF was precipitated under these conditions, whereas < 1.0% of llIIn-BSA could be precipitated.
RESULTS
As described previously (Minematsu et al., 1992 (Minematsu et al., , 1993 Meadows et ai., 1994) , infarcts produced by permanent intraarterial suture occlusion of the MCA involved large regions of the lateral cerebral cortex and underlying caudoputamen in the ipsilat eral hemisphere. Overall, infarct volume was re duced (ca. 50%) in bFGF-treated versus control an imals (I = 3.5, df = 21, p = 0.002; Table 1 ). This effect was seen to a similar degree in both cortex and caudoputamen and among all brain slices ex amined (Table 1) .
Similarly, neurological deficit at 24 h after isch emia was reduced in bFGF-treated versus control animals (z = 2. 6, p = 0.009; Table 2 ). There were no changes in physiological parameters between these groups, with the exception of a moderate (20-25%) decrease in blood pressure during bFGF infu sion ( Table 2) .
Core temperature was monitored and kept con stant in both bFGF-treated and control animals. To examine possible independent effects of bFGF on brain temperature, we directly monitored cortical temperature in a separate group of intact rats (N = 3) both before and at 30-min intervals for 3 h during intravenous bFGF infusion. We found no differ ences in brain temperature over time in these ani mals [F(2,14) = 0.3, n.s.).
To determine whether systemically administered bFGF might cross the damaged blood-brain barrier to enter ischemic tissue, lIIIn-bFGF was infused intravenously in three animals for 30 min, starting at 3 h after the onset of ischemia (corresponding to the last 30 min of the infusion period in treated animals; see above). Four hours later, brains were removed, sectioned, and subjected to autoradiography.
Gamma counting showed that only a small fraction of the total administered dose of radioactivity (0.01 ± 0.004%) was present in brain at the time of sac rifice. Autoradiography showed that this radioactiv ity was localized at the site of suture occlusion of the MCA and, in addition, was visualized faintly in the cortex and striatum and more intensely in the hippocampus of the ischemic (right) but not the nonischemic (left) hemisphere (Fig. 1) . To verify that the radioactivity found in brain remained asso ciated with bFGF, one additional animal underwent ischemia surgery and received intravenous III In bFGF, and labeled bFGF in brain homogenate was immunoprecipitated using specific anti-bFGF se rum. Under the conditions used, 30% of the total radioactivity in the homogenate was precipitated (equivalent to 60% of the amount of labeled bFGF standard that could be immunoprecipitated under the same conditions). These data indicate that at least some of the radioactivity found in brain re mained associated with bFGF. (Jiang et al., 1995) .
DISCUSSION
The dose of bFGF chosen for the current studies of intravenous administration (45 I-Lg/kg/h for 3 h) was considerably higher than that used in previous studies of direct intracerebral administration (see above) and was chosen empirically as a dose that might be high enough to maximize potential infarct reducing effects while avoiding significant side ef fects. In particular, Cuevas et al. (1991) found that 300 ng of bFGF administered as a rapid intravenous bolus to mature rats (equivalent to about I J,Lg/kgl min) resulted in a significant drop in systemic blood pressure. Since lowered systemic blood pressure might be expected to increase infarct size after focal cerebral ischemia. we chose a dose (45 J,Lg/kg/h. or 0.75 J,Lg/kg/min) that was below the reported hy-potensive dose. On the other hand. it was antici pated that the administered dose of intravenous bFGF might be high enough to cross the damaged blood-brain barrier and enter ischemic brain tissue at a sufficient concentration to exert potential in farct-reducing effects. Indeed. our results using ra diolabeled bFGF showed that while intravenous bFGF did not enter the intact hemisphere, it did enter regions of the ischemic hemisphere, including the cortex, striatum, and especially, hippocampus. reached ischemic brain tissue, this means that up to 4.5 ng of bFGF might be available. Assuming an extracellular hemispheric volume of 1 ml, the bFGF concentration would then be 4.5 ng/ml. In vitro, bFGF has potent neurotrophic and neuroprotective effects at concentrations of 1-10 ng/ml (Walicke, 1988; Mattson et aI., 1989; Freese et aI., 1992; Fin klestein et aI., 1993) .
Potential mechanisms of bFGF-induced reduc tion in infarct size include (a) direct protective ef fects on brain cells, including neurons, and (b) ef fects on cerebrovascular tone and cerebral blood flow (CBF). At least one of the currently identified high-affinity bFGF receptors (jlg) is widely distrib uted on neurons and on endothelial cells in the in tact rodent brain and, also, becomes localized on glia after brain injury or ischemia (Wanaka et aI.,
1990
; Logan et aI., 1992; Endoh et aI., 1994) . As noted above, bFGF is a potent neurotrophic factor that also protects neurons against a number of tox ins and insults in vitro, including anoxia, hypogly cemia, EAAs, Ca2+ ionophore, free radicals, and nitric oxide (NO) (Mattson et aI., 1989; Freese et aI., 1992; Finklestein et aI., 1993; Maiese et aI., 1993; Mattson and Scheff, 1994) . In particular, EAAs, NO, and free radicals are thought to play important roles in the pathogenesis of neuronal death after ischemia (Choi and Hartley, 1993) . AI-though the molecular mechanism of neuroprotec tion by bFGF is incompletely understood, it may depend on new neuronal gene transcription and pro tein synthesis (Mattson et al. , 1989) . Neurons at the margins ("penumbra" ) of focal infarcts appear to retain the capacity for synthesis of at least some cellular proteins [e. g. , heat shock proteins ]. and it is possible that bFGF reduces infarct size, in part, through direct effects on these cells.
Basic FGF also has trophic effects on brain glial and endothelial cells (Pettman et aI. , 1985; Gospo darowicz et aI. , 1986) , and it is possible that bFGF protects these cells by similar mechanisms. Indeed, the focal infarcts observed in the current study in volved all brain cellular elements, including neu rons, glia, and endothelia ("pannecrosis" ), so that the infarct-reducing effects of bFGF may have been due to direct protective effects on all of these cell types. As noted above, our radiolabeling data indi cate that intravenously administered bFGF may have entered ischemic brain tissue at concentra tions sufficiently high enough to be compatible with the trophic effects of bFGF observed in in vitro studies.
Another possible mechanism of bFGF-induced reduction in infarct size is through regulation of ce rebrovascular tone and CBF. As noted above intra venous bFGF (at doses of 300--1,000 ng as a single bolus) lowers blood pressure by systemic vasodila tion in mature rats, and recent studies show that topically applied bFGF (at doses of 5-200 ng/ml) is a potent dilator of cerebral pial arterioles through NO-dependent mechanisms (Cuevas et aI. , 1991; Rosenblatt et aI. , 1994) . Although the dose of intra venous bFGF administered in the current study was chosen to be below that previously reported to cause hypotension in rats (Cuevas et aI. , 1991) , we nonetheless saw a moderate but significant drop in MABP in bFGF-treated animals. However, in spite of this drop in MABP (and presumably also in ce rebral perfusion pressure), we also saw smaller in farcts in bFGF-treated animals. These data suggest that, at the dose used, bFGF may have a greater dilatory effect on cerebral than systemic vessels, thus resulting in a net increase in CBF.
Other potential questions concerning the effects of bFGF administration following focal ischemia in clude a possible delay in the evolution of infarct size and the possible long-term effects of bFGF. Since infarct volume was assessed only 24 h after isch emia in the current study, it might be argued that the effect of bFGF is simply to delay the eventual evolution of cerebral infarcts. However, in recent studies using a reperfusion model of focal ischemia, we found that the infarct-reducing effects of bFGF were the same whether animals were sacrificed at 2 days or at 1 week following ischemia (Jiang et aI. , 1995) . In addition, since bFGF is both a potent glial and a potent endothelial mitogen (Pettman et aI. , 1985; Gospodarowicz et aI. , 1986) , the exogenous administration of this factor might be expected to promote tumor formation in brain. However, in other studies in models of focal ischemia, we found no evidence of tumor formation following 4 days of continuous intraventricular infusion of bFGF or at 1
week following a 3-h infusion of intravenous bFGF (Koketsu et aI. , 1994; Jiang et aI., 1995) . Moreover, although other investigators have reported both glial and vascular proliferation in brain following long-term (up to I-month) intracerebral bFGF ad ministration, no tumor formation or other adverse histological or physiological consequences were re ported in these studies (Barotte et aI. , 1989; Puu mala et aI. , 1990) .
Clearly, further studies are required to clarify the phenomenon and mechanisms of reduction in in farct size by bFGF, as well as the possible long term consequences of bFGF administration. None theless, our current findings suggest that the intra venous administration of bFGF may represent a new approach to the treatment of focal cerebral ischemia.
